Literature DB >> 9633022

Parathyroid hormone suppression by 22-oxacalcitriol in the severe parathyroid hyperplasia.

H Funahashi1, Y Tanaka, T Imai, M Wada, K Tsukamura, Y Hayakawa, N Matsuura, T Kikumori, M Oiwa, Y Tominaga, H Takagi.   

Abstract

The suppression of parathyroid hormone (PTH) secretion by the administration of 1,25-dihydroxyvitamin D [1,25(OH)2D3] and 22-oxacalcitriol (OCT) was evaluated in nude mice transplanted with human hyperplastic parathyroid tissue. The parathyroid tissue was obtained for transplantation from a patient with severe secondary hyperparathyroidism who had undergone a parathyroidectomy. Tissue specimens were transplanted into the gluteus muscle of female nude mice. Animals were divided into two groups; one group was fed a normal diet, and the other group was fed a low calcium diet during the administration of OCT and 1,25(OH)2D3. OCT and 1,25(OH)2D3 were intraperitoneally administered two times every week, for a total of eight times. Serum calcium and phosphate levels were significantly higher in the mouse administered 1,25(OH)2D3 than in the mouse administered OCT. Serum alkaline phosphatase activity was elevated similarly in the mouse administered either OCT or 1,25(OH)2D3. OCT strongly suppressed human PTH secretion from the graft in mice with normal serum calcium levels as did 1,25(OH)2D3. However, human PTH secretion from the graft was stimulated by the administration of a low-calcium diet, despite OCT and 1,25(OH)2D3 administration. In summary, OCT and 1,25(OH)2D3 suppress PTH secretion even from severe secondary hyperplastic parathyroid tissue only in mice with normal or high calcium serum levels.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9633022     DOI: 10.1007/BF03347285

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  22 in total

1.  Suppression of PTH and decreased action on bone are partially responsible for the low calcemic activity of 22-oxacalcitriol relative to 1,25-(OH)2D3.

Authors:  J L Finch; A J Brown; T Mori; Y Nishii; E Slatopolsky
Journal:  J Bone Miner Res       Date:  1992-07       Impact factor: 6.741

2.  Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure.

Authors:  S Lopez-Hilker; T Galceran; Y L Chan; N Rapp; K J Martin; E Slatopolsky
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

3.  Induction of vitamin D 24-hydroxylase messenger RNA and activity by 22-oxacalcitriol in mouse kidney and duodenum. Possible role in decrease of plasma 1 alpha,25-dihydroxyvitamin D3.

Authors:  N Akeno; S Saikatsu; S Kimura; N Horiuchi
Journal:  Biochem Pharmacol       Date:  1994-11-29       Impact factor: 5.858

4.  Heterotransplantation of human parathyroid glands into nude mice.

Authors:  Y Tanaka; H Funahashi; T Imai; J Tobinaga; H Murase; H Andoh; M Wada; T Matsuyama; Y Tominaga; H Takagi
Journal:  Endocr J       Date:  1995-02       Impact factor: 2.349

Review 5.  Molecular genetics of hyperparathyroid disease.

Authors:  Y Tominaga; H Takagi
Journal:  Curr Opin Nephrol Hypertens       Date:  1996-07       Impact factor: 2.894

6.  The 1,25-dihydroxy-vitamin D3 receptor is phosphorylated in response to 1,25-dihydroxy-vitamin D3 and 22-oxacalcitriol in rat osteoblasts, and by casein kinase II, in vitro.

Authors:  P W Jurutka; C M Terpening; M R Haussler
Journal:  Biochemistry       Date:  1993-08-17       Impact factor: 3.162

7.  Differential effects of 1,25-(OH)2D3 and 22-oxacalcitriol on phosphate and calcium metabolism.

Authors:  J L Finch; A J Brown; N Kubodera; Y Nishii; E Slatopolsky
Journal:  Kidney Int       Date:  1993-03       Impact factor: 10.612

8.  22-Oxacalcitriol does not interfere with parathyroid hormone-induced phosphaturia or cyclic-AMP excretion.

Authors:  M M Friedlaender; Y Yagil; H Wald; M M Popovtzer
Journal:  Bone       Date:  1995-09       Impact factor: 4.398

9.  Interaction between calcium and 1,25-dihydroxyvitamin D3 in the regulation of preproparathyroid hormone and vitamin D receptor messenger ribonucleic acid in avian parathyroids.

Authors:  J Russell; A Bar; L M Sherwood; S Hurwitz
Journal:  Endocrinology       Date:  1993-06       Impact factor: 4.736

10.  The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion.

Authors:  A J Brown; C R Ritter; J L Finch; J Morrissey; K J Martin; E Murayama; Y Nishii; E Slatopolsky
Journal:  J Clin Invest       Date:  1989-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.